{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T08:23:20Z","timestamp":1769934200069,"version":"3.49.0"},"reference-count":13,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n            <jats:title>OBJECTIVES:<\/jats:title>\n            <jats:p>To identify and characterize clinical decline after completion of dexamethasone in severe COVID-19 and determine whether interleukin (IL)-6 and other inflammatory biomarkers predict the occurrence of clinical decline.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>DESIGN:<\/jats:title>\n            <jats:p>Prospective observational cohort.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>SETTING:<\/jats:title>\n            <jats:p>ICUs in three University of Washington affiliated hospitals between July 2020 and April 2021.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>PATIENTS:<\/jats:title>\n            <jats:p>Patients admitted to an ICU with COVID-19 who completed a course of dexamethasone.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>MEASUREMENTS AND MAIN RESULTS:<\/jats:title>\n            <jats:p>We identified 65 adult patients with severe COVID-19 who completed a 10-day course of dexamethasone, of whom 60 had plasma samples collected within 3 days of dexamethasone completion. We measured IL-6 with a clinical-grade electrochemiluminescent assay and a larger panel of inflammatory biomarkers (IL-8, Monocyte Chemoattractant Protein-1, Monocyte Inflammatory Protein-1 alpha, interferon gamma, C-X-C Motif Chemokine Ligand 10, WBC, bicarbonate) with a research immunoassay. We defined clinical decline by the occurrence of incident severe kidney injury, incident or escalating shock or fever, worsening hypoxemia, or death within 5 days of completion of dexamethasone. We estimated risk for clinical decline by standardized log<jats:sub>2<\/jats:sub> transformed biomarker concentration using multivariable logistic regression. Clinical decline post-dexamethasone was common, occurring in 49% of patients (<jats:italic toggle=\"yes\">n<\/jats:italic> = 32). Among all biomarkers, IL-6 levels were most strongly associated with clinical decline. After adjustment for age, sex, and study site, the odds of post-dexamethasone clinical decline were 7.33 times higher per one <jats:sc>sd<\/jats:sc> increase in log2 transformed IL-6 concentrations (adjusted odds ratio, 7.33; CI, 2.62\u201320.47; <jats:italic toggle=\"yes\">p<\/jats:italic> &lt; 0.001). The discriminatory power of IL-6 for clinical decline was high (cross-validated mean area under the receiver operating characteristic curve, 0.90; 95% CI, 0.79\u20130.95).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSIONS:<\/jats:title>\n            <jats:p>Clinical decline after completion of dexamethasone for severe COVID-19 is common. IL-6 concentrations obtained prior to completion of dexamethasone may have utility in identifying those at highest risk for subsequent worsening. If validated, future work might test whether plasma IL-6 could be used as a tool for a personalized approach to duration of dexamethasone treatment in severe COVID-19.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/cce.0000000000000813","type":"journal-article","created":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T19:05:22Z","timestamp":1697742322000},"page":"e0813","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Plasma Interleukin-6 Predicts Clinical Decline After Completion of Dexamethasone Therapy in Severe COVID-19"],"prefix":"10.1097","volume":"4","author":[{"given":"F. Linzee","family":"Mabrey","sequence":"first","affiliation":[{"name":"Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, University of Washington, Seattle, WA."},{"name":"Sepsis Center of Research Excellence-UW (SCORE-UW), University of Washington, Seattle, WA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pavan K.","family":"Bhatraju","sequence":"additional","affiliation":[{"name":"Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, University of Washington, Seattle, WA."},{"name":"Sepsis Center of Research Excellence-UW (SCORE-UW), University of Washington, Seattle, WA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric D.","family":"Morrell","sequence":"additional","affiliation":[{"name":"Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, University of Washington, Seattle, WA."},{"name":"Sepsis Center of Research Excellence-UW (SCORE-UW), University of Washington, Seattle, WA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leila R.","family":"Zelnick","sequence":"additional","affiliation":[{"name":"Kidney Research Institute (KRI), Division of Nephrology, Department of Medicine, University of Washington, Seattle, WA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neha A.","family":"Sathe","sequence":"additional","affiliation":[{"name":"Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, University of Washington, Seattle, WA."},{"name":"Sepsis Center of Research Excellence-UW (SCORE-UW), University of Washington, Seattle, WA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas G.","family":"O\u2019Connor","sequence":"additional","affiliation":[{"name":"Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, University of Washington, Seattle, WA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Mikacenic","sequence":"additional","affiliation":[{"name":"Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, University of Washington, Seattle, WA."},{"name":"Sepsis Center of Research Excellence-UW (SCORE-UW), University of Washington, Seattle, WA."},{"name":"Translational Research, Benaroya Research Institute, Seattle, WA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas R.","family":"Martin","sequence":"additional","affiliation":[{"name":"Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, University of Washington, Seattle, WA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W. Conrad","family":"Liles","sequence":"additional","affiliation":[{"name":"Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, University of Washington, Seattle, WA."},{"name":"Sepsis Center of Research Excellence-UW (SCORE-UW), University of Washington, Seattle, WA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark M.","family":"Wurfel","sequence":"additional","affiliation":[{"name":"Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, University of Washington, Seattle, WA."},{"name":"Sepsis Center of Research Excellence-UW (SCORE-UW), University of Washington, Seattle, WA."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2022,12,14]]},"reference":[{"key":"R2-20240807","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJMoa2021436","article-title":"Dexamethasone in hospitalized patients with Covid-19.","volume":"384","author":"Horby","year":"2021","journal-title":"N Engl J Med"},{"key":"R3-20240807","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1056\/NEJMoa2100433","article-title":"Interleukin-6 receptor antagonists in critically ill patients with Covid-19.","volume":"384","author":"Gordon","year":"2021","journal-title":"N Engl J Med"},{"key":"R4-20240807","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the treatment of Covid-19 - final report.","volume":"383","author":"Beigel","year":"2020","journal-title":"N Engl J Med"},{"key":"R5-20240807","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1001\/jama.2020.17022","article-title":"Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: The REMAP-CAP COVID-19 corticosteroid domain randomized clinical trial.","volume":"324","author":"Angus","year":"2020","journal-title":"JAMA"},{"key":"R6-20240807","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1038\/s41591-020-1051-9","article-title":"An inflammatory cytokine signature predicts COVID-19 severity and survival.","volume":"26","author":"Del Valle","year":"2020","journal-title":"Nat Med"},{"key":"R7-20240807","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/S2213-2600(20)30366-0","article-title":"Prevalence of phenotypes of acute respiratory distress syndrome in critically ill patients with COVID-19: A prospective observational study.","volume":"8","author":"Sinha","year":"2020","journal-title":"Lancet Respir Med"},{"key":"R8-20240807","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/s41577-020-0346-x","article-title":"Dysregulation of type I interferon responses in COVID-19.","volume":"20","author":"Acharya","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"R9-20240807","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1126\/science.abc6027","article-title":"Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients.","volume":"369","author":"Hadjadj","year":"2020","journal-title":"Science"},{"key":"R10-20240807","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1164\/rccm.202105-1302OC","article-title":"Latent class analysis reveals COVID-19-related acute respiratory distress syndrome subgroups with differential responses to corticosteroids.","volume":"204","author":"Sinha","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"R11-20240807","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s13054-021-03873-2","article-title":"Early, biomarker-guided steroid dosing in COVID-19 pneumonia: A pilot randomized controlled trial.","volume":"26","author":"Odeyemi","year":"2022","journal-title":"Crit Care"},{"key":"R12-20240807","doi-asserted-by":"crossref","first-page":"L14","DOI":"10.1152\/ajplung.00049.2022","article-title":"Chemokines, soluble PD-L1, and immune cell hyporesponsiveness are distinct features of SARS-CoV-2 critical illness.","volume":"323","author":"Morrell","year":"2022","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"R13-20240807","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1378\/chest.128.2.525","article-title":"Causes and timing of death in patients with ARDS.","volume":"128","author":"Stapleton","year":"2005","journal-title":"Chest"},{"key":"R14-20240807","doi-asserted-by":"crossref","first-page":"114224","DOI":"10.1016\/j.jviromet.2021.114224","article-title":"Performance of the Roche IL-6 chemiluminescent immunoassay in patients with COVID-like respiratory symptoms.","volume":"296","author":"Lau","year":"2021","journal-title":"J Virol Methods"}],"container-title":["Critical Care Explorations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CCE.0000000000000813","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T14:14:52Z","timestamp":1723040092000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CCE.0000000000000813"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":13,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/cce.0000000000000813","relation":{},"ISSN":["2639-8028"],"issn-type":[{"value":"2639-8028","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12]]}}}